DANIEL G TENEN, M.D.
Osteopathic Medicine at Brookline Ave, Boston, MA

5502176, Mar 26, 1996

Apr 14, 1993

8/049283

Daniel G. Tenen - Boston MA
Heike L. Pahl - Cambridge MA
Timothy C. Burn - Bedford MA

Beth Israel Hospital, Boston Association - Boston MA

C07H 2104, C12N 516, C12N 1585

536 241

The subject application is drawn to a method of transfecting a myeloid cell line and a method of producing a selected product in a myeloid cell. The invention also includes myeloid cell specific promoters and enhancers, and constructs which contain these promoters and enhancers. The invention further includes a myeloid cell specific promoter-heterologous gene construct, where the expression of the heterologous gene is under the control of the myeloid cell specific promoter. The invention also includes a transgenic non-human mammal in which myeloid cells express a protein encoded by a heterologous gene. Finally the invention includes a method for identifying factors that can regulate myeloid cell specific transcription.

5556954, Sep 17, 1996

Dec 15, 1992

7/990965

Timothy C. Burn - Bedford MA
Anne B. Satterthwaite - Brighton MA
Daniel G. Tenen - Boston MA

Beth Israel Hospital Boston Association - Boston MA

C07H 2104, C12N 510, C12N 1585

536 241

The subject application relates to a hematopoietic stem cell specific promoter and to a hematopoietic stem cell specific enhancer and to uses therefor. The invention also includes a hematopoietic stem cell specific promoter-heterologous gene construct, where the expression of the heterologous gene is under the control of the myeloid cell type specific promoter. Additionally, the application is drawn to a method of expressing a heterologous gene in a hematopoietic stem cell. The invention further includes a method of expressing a selected heterologous gene product in hematopoietic stem cells in an individual. The invention also includes a transgenic non-human mammal in which the hematopoietic stem cells express a protein encoded by a heterologous gene. Finally the invention includes a method for identifying factors which can regulate hematopoietic stem cell specific transcription.

5242807, Sep 7, 1993

Nov 1, 1989

7/430501

Steven J. Ackerman - Sharon MA
Helene F. Rosenberg - Brighton MA
Daniel G. Tenen - Boston MA

Beth Israel Hospital Association - Boston MA

C07H 2104, C12N 914, C12N 1555, C12N 1566

435 691

A recombinant DNA molecule consisting of segments of DNA from different genomes which have been joined end-to-end outside of living cells, and the progeny of such a recombinant DNA molecule, which recombinant DNA molecule (1) has the capacity to infect a host cell and to be maintained therein, and (2) comprises a DNA coding sequence selected from the group consisting of: (a) the CLCP-encoding sequence shown in FIG. 1, (b) a DNA sequence which hybridizes to the CLCP-encoding sequence shown in FIG. 1, and which encodes a polypeptide which (i) cross-reacts with an antibody to CLCP or to denatured CLCP, (ii) exhibits lysophospholipase activity, and (iii) forms dipyramidal crystals under conditions permitting CLC formation; and (c) a DNA sequence encoding a polypeptide encoded by any of the foregoing DNA sequences.